FDA grants priority review to Roche ’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer

Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

This article reviewed the predictive value of TMB and its limitations in the field of immunotherapy for lung cancer. DOI: 10.3779/j.issn.1009-3419.2019.06.08
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Authors: Rocco D, Della Gravara L, Battiloro C, Gridelli C Abstract Introduction: Even with the currently recommended chemotherapeutic and immunotherapeutic treatment, the five year survival rate for advanced nonsquamous and squamous NSCLC without oncogenic drivers remains poor. However, several different chemo-immunotherapy combinations are presently being investigated - with favorable results- in order to increase the PFS and OS rates of these patients. Areas covered: Therefore, this paper aims to discuss the most promising trials investigating chemo-immunotherapy combinations and their present and future impact ...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Immunotherapy, Ahead of Print.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
Conclusion and outlookThe case presented here is of interest as it adopts a  novel immunotherapeutic approach to HAC, yielding a promising outcome. This highlights the importance of molecular typing and immunohistochemical profiling in the diagnosis and management of non-small cell lung cancer.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. Biomed Res Int. 2019;2019:9056417 Authors: Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U, Group IY Abstract Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a larg...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Condition:   Metastatic Non-Small Cell Lung Cancer Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: Docetaxel Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study quantifies the disturbing trend that, despite the expansion in the number of patients eligible for expensive and potentially toxic ICIs [immune checkpoint inhibitors], the ratio of those benefiting is decreasing,” wrote Dr. Daniel V.T. Catenacci, co-author of an editorial that accompanied the study in JAMA Network. “Observations in this article are sobering and remind us to keep expectations realistic.” Both Catenacci and Haslem agreed that the study should serve as a reminder to patients, physicians and policy makers to have more realistic discussions about the use of, and expectations of, the...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Opinion statementTargeted therapies and more recently immune checkpoint inhibitors (ICI) have transformed the treatment landscape of advanced NSCLC. Clinical trials investigating immune checkpoint inhibitors (ICI) have usually excluded patients with oncogenic drivers, so that the outcome of these agents in this population is poorly known. In patients with oncogenic addiction, targeted therapy remains clearly the best option, and the place of immunotherapy in this population has not been clearly defined yet.Based on available data, we suggest that (i) immunotherapy single agent should be proposed only after exhaustion of mo...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
We report for the first time a negativation of PDL-1 status in 2 cases of stage IIIA NSCLC with conversion to operable disease after using immunotherapy. The first patient was a 59-year old female diagnosed incidentally to have stage IIIA inoperable NSCLC that was treated with combination chemo-immunotherapy, and converted to operable disease with a negative PD-L1 in the postoperative setting. The second case is that of a 56-year old male that also had an inoperable stage IIIA NSCLC treated with chemotherapy first line followed by pembrolizumab at progression, then operated after surgical conversion, with negative PD-L1 po...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Bayraktar S, Batoo S, Okuno S, Glück S Abstract The idea of using the immune system to fight cancer is over 100 years old. A new molecular approach led to a better understanding of the immune system. Checkpoint regulation, understanding the roles of Tregs, Th1, and Th2, development of Chimeric antigen receptor (CAR)-T cells, as well as regulation of dendritic cells and macrophages, are just a few examples of our understating that has also led to the discovery of immune checkpoint inhibitors (ICIs) and modulators. This led the Nobel Prize committee in 2018, to award Dr. James P. Allison the Nobel Prize...
Source: Journal of Carcinogenesis - Category: Cancer & Oncology Tags: J Carcinog Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Grants | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals